{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:49:41Z","timestamp":1790808581754,"version":"4.1.0"},"reference-count":170,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Antithrombotic therapy is a delicate balance between the benefits of preventing a thrombotic event and the risks of inducing a major bleed. Traditional approaches have included antiplatelet and anticoagulant medications, require careful dosing and monitoring, and all carry some risk of bleeding. In recent years, several new targets have been identified, both in the platelet and coagulation systems, which may mitigate this bleeding risk. In this review, we briefly describe the current state of antithrombotic therapy, and then present a detailed discussion of the new generation of drugs that are being developed to target more safely existing or newly identified pathways, alongside the strategies to reverse direct oral anticoagulants, showcasing the breadth of approaches. Combined, these exciting advances in antithrombotic therapy bring us closer than we have ever been to the \u201choly grail\u201d of the field, a treatment that separates the hemostatic and thrombotic systems, preventing clots without any concurrent bleeding risk.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1272971","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T11:26:13Z","timestamp":1698060373000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Novel strategies in antithrombotic therapy: targeting thrombosis while preserving hemostasis"],"prefix":"10.3389","volume":"10","author":[{"given":"Martha M. S.","family":"Sim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semekidus","family":"Shiferawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/eurheartj\/ehw550","article-title":"Thrombosis and platelets: an update","volume":"38","author":"Koupenova","year":"2016","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/hae.12427","article-title":"Primary haemostasis: newer insights","volume":"20","author":"Berndt","year":"2014","journal-title":"Haemophilia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1161\/01.ATV.0000095974.95122.EC","article-title":"Platelets in inflammation and thrombosis","volume":"23","author":"Wagner","year":"2003","journal-title":"Arterioscl Thromb Vasc Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1161\/ATVBAHA.118.310955","article-title":"Novel antiplatelet therapies for atherothrombotic diseases","volume":"39","author":"Majithia","year":"2019","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/1074248419899314","article-title":"Novel antiplatelet agents in cardiovascular disease","volume":"25","author":"Tscharre","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13079","DOI":"10.3390\/ijms222313079","article-title":"Current and novel antiplatelet therapies for the treatment of cardiovascular diseases","volume":"22","author":"Jourdi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"115297","DOI":"10.1016\/j.bcp.2022.115297","article-title":"Novel approaches to antiplatelet therapy","volume":"206","author":"Gresele","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"B8","first-page":"179","article-title":"The discovery of aspirin\u2019s antithrombotic effects","volume":"34","author":"Miner","year":"2007","journal-title":"Tex Heart Inst J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/01.ATV.0000104005.92603.f2","article-title":"Cyclooxygenase-2 expression and inhibition in atherothrombosis","volume":"24","author":"Cipollone","year":"2004","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1182\/blood-2006-01-010645","article-title":"Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions","volume":"109","author":"Undas","year":"2007","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","author":"Farid","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","article-title":"Clopidogrel pathway","volume":"20","author":"Sangkuhl","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40119-020-00197-0","article-title":"Dual antiplatelet therapy in coronary artery disease","volume":"9","author":"Sharma","year":"2020","journal-title":"Cardiol Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev-pharmtox-051921-092701","article-title":"Pharmacogenetics of antiplatelet therapy","volume":"63","author":"Castrichini","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40256-022-00565-2","article-title":"CYP2C9 Polymorphisms and the risk of cardiovascular events in patients treated with clopidogrel: combined data from the POPular genetics and POPular AGE trials","volume":"23","author":"van den Broek","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.2174\/1381612822666151208120106","article-title":"Antiplatelet agents in cardiology: a report on aspirin, clopidogrel, prasugrel, and ticagrelor","volume":"22","author":"Dobesh","year":"2016","journal-title":"Curr Pharm Des"},{"key":"B21","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet (London, England)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/jnnp.2008.143875","article-title":"Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk","volume":"79","author":"Halkes","year":"2008","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-015-0425-7","article-title":"Platelet GP IIb-IIIa receptor antagonists in primary angioplasty: back to the future","volume":"75","author":"De Luca","year":"2015","journal-title":"Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2217\/fca.15.50","article-title":"Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development","volume":"11","author":"Franchi","year":"2015","journal-title":"Future Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1093\/eurheartj\/ehz807","article-title":"Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes","volume":"41","author":"Storey","year":"2020","journal-title":"Eur Heart J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1016\/j.jacc.2020.03.059","article-title":"Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction","volume":"75","author":"Sinnaeve","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1021\/jm400820m","article-title":"Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. Separation of the antithrombotic effect and bleeding for candidate drug AZD1283","volume":"56","author":"Bach","year":"2013","journal-title":"J Med Chem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.thromres.2014.06.034","article-title":"SAR216471, An alternative to the use of currently available P2Y\u2081\u2082 receptor inhibitors?","volume":"134","author":"Delesque-Touchard","year":"2014","journal-title":"Thromb Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1182\/blood.V100.6.2071","article-title":"Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb\/IIIa","volume":"100","author":"Bougie","year":"2002","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/01.ATV.0000255307.65939.59","article-title":"A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb\/IIIa) antagonists","volume":"27","author":"Bassler","year":"2007","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1161\/ATVBAHA.114.303724","article-title":"RUC-4: a novel \u03b1IIb\u03b23 antagonist for prehospital therapy of myocardial infarction","volume":"34","author":"Li","year":"2014","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"125ra32","DOI":"10.1126\/scitranslmed.3003576","article-title":"Structure-guided design of a high-affinity platelet integrin \u03b1IIb\u03b23 receptor antagonist that disrupts mg\u00b2+ binding to the MIDAS","volume":"4","author":"Zhu","year":"2012","journal-title":"Sci Transl Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e016552","DOI":"10.1161\/JAHA.120.016552","article-title":"First human use of RUC-4: a nonactivating second-generation small-molecule platelet glycoprotein IIb\/IIIa (integrin \u03b1IIb\u03b23) inhibitor designed for subcutaneous point-of-care treatment of ST-segment-elevation myocardial infarction","volume":"9","author":"Kereiakes","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/09537104.2017.1293804","article-title":"Synergistic effect of peptide inhibitors derived from the extracellular and intracellular domain of \u03b1(IIb) subunit of integrin \u03b1(IIb)\u03b2(3) on platelet activation and aggregation","volume":"29","author":"Gkourogianni","year":"2018","journal-title":"Platelets"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/nm760","article-title":"Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation","volume":"8","author":"Covic","year":"2002","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.tips.2017.05.001","article-title":"Targeting PAR1: now what?","volume":"38","author":"Flaumenhaft","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1161\/ATVBAHA.120.315168","article-title":"PAR1 (protease-activated receptor 1) pepducin therapy targeting myocardial necrosis in coronary artery disease and acute coronary syndrome patients undergoing cardiac catheterization: a randomized, placebo-controlled, phase 2 study","volume":"40","author":"Kuliopulos","year":"2020","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"32553","DOI":"10.1074\/jbc.M113.472373","article-title":"Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by alpha-thrombin","volume":"288","author":"Arachiche","year":"2013","journal-title":"J Biol Chem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"8843","DOI":"10.1021\/acs.jmedchem.2c00359","article-title":"Discovery of two novel antiplatelet clinical candidates (BMS-986120 and BMS-986141) that antagonize protease-activated receptor 4","volume":"65","author":"Priestley","year":"2022","journal-title":"J Med Chem"},{"key":"B43","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","article-title":"PAR4 (protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation","volume":"38","author":"Wilson","year":"2018","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1161\/CIRCULATIONAHA.105.587758","article-title":"Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis","volume":"113","author":"Leger","year":"2006","journal-title":"Circulation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"109889","DOI":"10.1016\/j.cbi.2022.109889","article-title":"3,5,2\u2032,4\u2032-Tetramethoxystilbene, a fully methylated resveratrol analog, prevents platelet aggregation and thrombus formation by targeting the protease-activated receptor 4 pathway","volume":"357","author":"Chiang","year":"2022","journal-title":"Chem-Biol Interact"},{"key":"B46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0014-5793(97)00022-7","article-title":"The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells","volume":"403","author":"Leon","year":"1997","journal-title":"FEBS Lett"},{"key":"B47","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1124\/jpet.105.094037","article-title":"MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2\u2032-deoxyadenosine-3\u2032,5\u2032-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice","volume":"316","author":"Hechler","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11239-015-1302-7","article-title":"The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys","volume":"41","author":"Wong","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/ATVBAHA.115.306885","article-title":"Synergistic inhibition of both P2Y1 and P2Y12 adenosine diphosphate receptors as novel approach to rapidly attenuate platelet-mediated thrombosis","volume":"36","author":"Gremmel","year":"2016","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1172\/JCI114318","article-title":"A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion","volume":"84","author":"Moroi","year":"1989","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1111\/j.1538-7836.2003.00495.x","article-title":"Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived fab fragments","volume":"1","author":"Lecut","year":"2003","journal-title":"J Thromb Haemost"},{"key":"B52","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/19420862.2017.1336592","article-title":"Design, development and characterization of ACT017, a humanized fab that blocks platelet\u2019s glycoprotein VI function without causing bleeding risks","volume":"9","author":"Lebozec","year":"2017","journal-title":"mAbs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00228-017-2264-9","article-title":"Anti-GPVI fab SAR264565 effectively blocks GPVI function in ex vivo human platelets under arterial shear in a perfusion chamber","volume":"73","author":"Florian","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1182\/blood-2004-06-2391","article-title":"Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice","volume":"105","author":"Gr\u00fcner","year":"2005","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1096\/fj.03-0464fje","article-title":"Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo","volume":"18","author":"Massberg","year":"2004","journal-title":"FASEB J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","article-title":"Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein VI, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1161\/STROKEAHA.121.037006","article-title":"Revacept, an inhibitor of platelet adhesion in symptomatic carotid stenosis: a multicenter randomized phase II trial","volume":"53","author":"Uphaus","year":"2022","journal-title":"Stroke"},{"key":"B58","doi-asserted-by":"publisher","first-page":"105661","DOI":"10.1016\/j.bioorg.2022.105661","article-title":"Identification of novel antiplatelet agents by targeting glycoprotein VI: a combined virtual screening study","volume":"121","author":"Ol\u011fa\u00e7","year":"2022","journal-title":"Bioorg Chem"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1111\/jth.15836","article-title":"Anti-GPVI nanobody blocks collagen- and atherosclerotic plaque-induced GPVI clustering, signaling, and thrombus formation","volume":"20","author":"Jooss","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B60","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1182\/blood.V95.3.903.003k37_903_910","article-title":"Requirement of leucine-rich repeats of glycoprotein (GP) ibalpha for shear-dependent and static binding of von willebrand factor to the platelet membrane GP ib-IX-V complex","volume":"95","author":"Shen","year":"2000","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-3-642-29423-5_12","article-title":"Inhibitors of the interaction between von willebrand factor and platelet GPIb\/IX\/V","volume":"210","author":"Gresele","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1161\/01.ATV.20.5.1347","article-title":"Antithrombotic effect of platelet glycoprotein ib-blocking monoclonal antibody fab fragments in nonhuman primates","volume":"20","author":"Cauwenberghs","year":"2000","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1160\/TH08-02-0073","article-title":"The humanized anti-glycoprotein ib monoclonal antibody h6B4-fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons","volume":"100","author":"Fontayne","year":"2008","journal-title":"Thromb Haemostasis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1160\/TH13-06-0490","article-title":"Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis","volume":"111","author":"Lei","year":"2014","journal-title":"Thromb Haemostasis"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1111\/bph.13178","article-title":"A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury","volume":"172","author":"Li","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1038\/s41598-021-91165-8","article-title":"In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIb\u03b1","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"B67","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/jth.15554","article-title":"Targeted SERPIN (TaSER): a dual-action antithrombotic agent that targets platelets for SERPIN delivery","volume":"20","author":"Sanrattana","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B68","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1161\/hq0102.101520","article-title":"Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von willebrand factor, in monkeys","volume":"22","author":"Kageyama","year":"2002","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1182\/blood.V99.10.3623","article-title":"Inhibition of the von willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons","volume":"99","author":"Wu","year":"2002","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1182\/blood-2012-11-464545","article-title":"Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the nanobody ALX-0081 reduces brain infarct size in Guinea pigs","volume":"121","author":"Momi","year":"2013","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12265-012-9435-y","article-title":"Novel antiplatelet agents: aLX-0081, a nanobody directed towards von willebrand factor","volume":"6","author":"Bartunek","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/j.1538-7836.2009.03459.x","article-title":"Inhibition of von willebrand factor-mediated platelet activation and thrombosis by the anti-von willebrand factor A1-domain aptamer ARC1779","volume":"7","author":"Diener","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B75","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1161\/ATVBAHA.111.237529","article-title":"ARC15105 Is a potent antagonist of von willebrand factor mediated platelet activation and adhesion","volume":"32","author":"Siller-Matula","year":"2012","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1038\/s41598-021-82747-7","article-title":"The aptamer BT200 blocks von willebrand factor and platelet function in blood of stroke patients","volume":"11","author":"Kovacevic","year":"2021","journal-title":"Sci Rep"},{"key":"B77","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1182\/bloodadvances.2022007805","article-title":"The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF\/FVIII in type 2B von willebrand disease","volume":"6","author":"Ay","year":"2022","journal-title":"Blood Adv"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.3324\/haematol.2019.235549","article-title":"Novel aptamer to von willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab","volume":"105","author":"Sakai","year":"2020","journal-title":"Haematologica"},{"key":"B79","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0968-0896(98)00038-8","article-title":"Adenosine receptors: new opportunities for future drugs","volume":"6","author":"Poulsen","year":"1998","journal-title":"Bioorg Med Chem"},{"key":"B80","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.3390\/ijms20215475","article-title":"Blood platelet adenosine receptors as potential targets for anti-platelet therapy","volume":"20","author":"Wolska","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"25993","DOI":"10.1074\/jbc.M702327200","article-title":"Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells","volume":"282","author":"Suzuki-Inoue","year":"2007","journal-title":"J Biol Chem"},{"key":"B82","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/jth.13987","article-title":"Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2\/podoplanin-dependent platelet aggregation and lung metastasis","volume":"16","author":"Sasaki","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B83","doi-asserted-by":"publisher","first-page":"42733","DOI":"10.18632\/oncotarget.5811","article-title":"Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"key":"B84","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/jth.13604","article-title":"C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice","volume":"15","author":"Shirai","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/2211253a0","article-title":"D-receptor for serotonin on blood platelets","volume":"221","author":"Michal","year":"1969","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/09537104.2018.1478072","article-title":"Autocrine and paracrine regulatory functions of platelet serotonin","volume":"29","author":"Mammadova-Bach","year":"2018","journal-title":"Platelets"},{"key":"B87","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1055\/s-0038-1646443","article-title":"Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models","volume":"66","author":"Hara","year":"1991","journal-title":"Thromb Haemost"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1161\/STROKEAHA.107.505131","article-title":"Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial","volume":"39","author":"Shinohara","year":"2008","journal-title":"Stroke"},{"key":"B89","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1124\/jpet.109.153189","article-title":"APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology","volume":"331","author":"Adams","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e87026","DOI":"10.1371\/journal.pone.0087026","article-title":"The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function","volume":"9","author":"Lin","year":"2014","journal-title":"PloS One"},{"key":"B91","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1055\/s-0037-1615615","article-title":"Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B\/5-HT2A receptor antagonist","volume":"85","author":"Berry","year":"2001","journal-title":"Thromb Haemost"},{"key":"B92","doi-asserted-by":"publisher","first-page":"E982","DOI":"10.1073\/pnas.1718600115","article-title":"PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury","volume":"115","author":"De Ceunynck","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/blood-2014-09-599910","article-title":"Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar","volume":"125","author":"Aisiku","year":"2015","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ehj.2003.08.021","article-title":"The adhesion molecule P-selectin and cardiovascular disease","volume":"24","author":"Blann","year":"2003","journal-title":"Eur Heart J"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1055\/s-0039-1692983","article-title":"Platelet-Neutrophil crosstalk in atherothrombosis","volume":"119","author":"Pircher","year":"2019","journal-title":"Thromb Haemost"},{"key":"B96","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1124\/jpet.107.128124","article-title":"Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis","volume":"324","author":"Bedard","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"B97","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.2147\/IJN.S316863","article-title":"Nanoparticles of a new small-molecule P-selectin inhibitor attenuate thrombosis, inflammation, and tumor growth in two animal models","volume":"16","author":"Feng","year":"2021","journal-title":"Int J Nanomed"},{"key":"B98","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e004255","DOI":"10.1161\/JAHA.116.004255","article-title":"Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention according to timing of infusion: insights from the SELECT-ACS trial","volume":"5","author":"St\u00e4hli","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B100","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1042\/BCJ20190402","article-title":"Phosphoinositide 3-kinases in platelets, thrombosis and therapeutics","volume":"477","author":"Ribes","year":"2020","journal-title":"Biochem J"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/blood-2009-04-217224","article-title":"Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in akt activation and thrombus formation in vitro and in vivo","volume":"115","author":"Martin","year":"2010","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2009-03-208074","article-title":"Genetic evidence for a predominant role of PI3Kbeta catalytic activity in ITAM- and integrin-mediated signaling in platelets","volume":"114","author":"Canobbio","year":"2009","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1111\/j.1538-7836.2012.04898.x","article-title":"Human target validation of phosphoinositide 3-kinase (PI3K)\u03b2: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K\u03b2 inhibitor","volume":"10","author":"Nylander","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B104","doi-asserted-by":"publisher","first-page":"734603","DOI":"10.3389\/fphar.2021.734603","article-title":"Berberine and its main metabolite berberrubine inhibit platelet activation through suppressing the class I PI3K\u03b2\/Rasa3\/Rap1 pathway","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"7399","DOI":"10.1021\/acs.jmedchem.2c00592","article-title":"protein kinase G\/vasodilator-stimulated phosphoprotein and phosphatidylinositol 3-kinase\/akt phosphorylation","volume":"65","author":"Fan","year":"2022","journal-title":"J Med Chem"},{"key":"B106","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1182\/blood-2011-06-360743","article-title":"Critical role for syk in responses to vascular injury","volume":"118","author":"Andre","year":"2011","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2217\/imt-2020-0215","article-title":"Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia","volume":"12","author":"Newland","year":"2020","journal-title":"Immunotherapy"},{"key":"B109","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.thromres.2022.02.020","article-title":"The effect of bruton\u2019s tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions","volume":"212","author":"Karel","year":"2022","journal-title":"Thromb Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12195-022-00723-1","article-title":"Ibrutinib inhibits BMX-dependent endothelial VCAM-1 expression in vitro and pro-atherosclerotic endothelial activation and platelet adhesion in vivo","volume":"15","author":"Kohs","year":"2022","journal-title":"Cell Mol Bioeng"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1182\/blood.V86.6.2168.bloodjournal8662168","article-title":"Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane","volume":"86","author":"Essex","year":"1995","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1182\/blood-2010-04-278184","article-title":"Endothelium-derived but not platelet-derived protein disulfide isomerase is required for thrombus formation in vivo","volume":"116","author":"Jasuja","year":"2010","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"23543","DOI":"10.1074\/jbc.M115.666180","article-title":"Quercetin-3-rutinoside inhibits protein disulfide isomerase by binding to its b'x domain","volume":"290","author":"Lin","year":"2015","journal-title":"J Biol Chem"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3389\/fphar.2019.01678","article-title":"Myricetin, the main flavonoid in syzygium cumini leaf, is a novel inhibitor of platelet thiol isomerases PDI and ERp5","volume":"10","author":"Gaspar","year":"2019","journal-title":"Front Pharmacol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood-2014-05-575878","article-title":"Platelet 12-LOX is essential for Fc\u03b3RIIa-mediated platelet activation","volume":"124","author":"Yeung","year":"2014","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1160\/TH13-01-0014","article-title":"12-lipoxygenase Activity plays an important role in PAR4 and GPVI-mediated platelet reactivity","volume":"110","author":"Yeung","year":"2013","journal-title":"Thromb Haemost"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1161\/ATVBAHA.117.309868","article-title":"First selective 12-LOX inhibitor, ML355, impairs thrombus formation and vessel occlusion in vivo with minimal effects on hemostasis","volume":"37","author":"Adili","year":"2017","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood.V76.1.1.1","article-title":"Surface-dependent reactions of the vitamin K-dependent enzyme complexes","volume":"76","author":"Mann","year":"1990","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0950-3536(05)80019-8","article-title":"Mechanisms of vitamin K antagonism","volume":"3","author":"Bovill","year":"1990","journal-title":"Baillieres Clin Haematol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/246355a0","article-title":"Anticoagulant action of heparin","volume":"246","author":"Damus","year":"1973","journal-title":"Nature"},{"key":"B121","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.beha.2012.06.004","article-title":"The promise of novel direct oral anticoagulants","volume":"25","author":"Hoffman","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.annemergmed.2013.05.026","article-title":"Rapid reversal of warfarin-associated hemorrhage in the emergency department by prothrombin complex concentrates","volume":"62","author":"Frumkin","year":"2013","journal-title":"Ann Emerg Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1160\/TH16-04-0266","article-title":"Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis","volume":"116","author":"Chai-Adisaksopha","year":"2016","journal-title":"Thromb Haemostasis"},{"key":"B124","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/17474086.2019.1624520","article-title":"Prothrombin complex concentrate for vitamin K antagonist reversal in acute bleeding settings: efficacy and safety","volume":"12","author":"Ostermann","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/trf.17010","article-title":"Vitamin K antagonist reversal strategies: systematic review and network meta-analysis from the AABB","volume":"62","author":"Pagano","year":"2022","journal-title":"Transfusion"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1177\/1060028020920855","article-title":"Emergent warfarin reversal with fixed-dose 4-factor prothrombin Complex concentrate","volume":"54","author":"Jansma","year":"2020","journal-title":"Ann Pharmacother"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jth.14772","article-title":"Vitamin K versus warfarin interruption alone in patients without bleeding and an international normalized ratio > 10","volume":"18","author":"Farrow","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B128","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.bja.2018.01.023","article-title":"Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review","volume":"120","author":"Boer","year":"2018","journal-title":"Br J Anaesth"},{"key":"B129","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/17425255.2016.1194395","article-title":"The toxicology of heparin reversal with protamine: past, present and future","volume":"12","author":"Sokolowska","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.thromres.2023.05.003","article-title":"OKL-1111, a modified cyclodextrin as a potential universal reversal agent for anticoagulants","volume":"227","author":"Meijers","year":"2023","journal-title":"Thromb Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1160\/TH14-08-0712","article-title":"Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab","volume":"113","author":"Honickel","year":"2015","journal-title":"Thromb Haemost"},{"key":"B133","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1160\/TH14-12-1080","article-title":"A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran","volume":"113","author":"Glund","year":"2015","journal-title":"Thromb Haemost"},{"key":"B134","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for Major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1076029619863493","DOI":"10.1177\/1076029619863493","article-title":"Reversal of factor Xa inhibitors by andexanet alfa may increase thrombogenesis compared to pretreatment values","volume":"25","author":"Siddiqui","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/rth2.12418","article-title":"Andexanet versus prothrombin complex concentrates: differences in reversal of factor Xa inhibitors in in vitro thrombin generation","volume":"4","author":"Lu","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"B138","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/nm.4149","article-title":"A rapid pro-hemostatic approach to overcome direct oral anticoagulants","volume":"22","author":"Thalji","year":"2016","journal-title":"Nat Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/jth.13673","article-title":"Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa(I16l))","volume":"15","author":"Parsons-Rich","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B140","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/STROKEAHA.120.029789","article-title":"Phase 1b study to evaluate safety, tolerability, and Maximum tolerated dose of PF-05230907 for intracerebral hemorrhage","volume":"52","author":"Silva Blas","year":"2021","journal-title":"Stroke"},{"key":"B141","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41467-017-00647-9","article-title":"Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors","volume":"8","author":"Verhoef","year":"2017","journal-title":"Nat Commun"},{"key":"B142","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/blood.2020007116","article-title":"Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants","volume":"137","author":"Ansell","year":"2021","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/eurheartj\/ehab637","article-title":"Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects","volume":"43","author":"Ansell","year":"2022","journal-title":"Eur Heart J"},{"key":"B144","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb Haemost"},{"key":"B145","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1055\/s-0037-1613783","article-title":"Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice","volume":"83","author":"Dewerchin","year":"2000","journal-title":"Thromb Haemost"},{"key":"B146","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood-2008-07-169003","article-title":"Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain","volume":"113","author":"Mullins","year":"2009","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.1073\/pnas.95.13.7597","article-title":"Prothrombin deficiency results in embryonic and neonatal lethality in mice","volume":"95","author":"Sun","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B148","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1126\/science.1652157","article-title":"Factor XI activation in a revised model of blood coagulation","volume":"253","author":"Gailani","year":"1991","journal-title":"Science"},{"key":"B149","doi-asserted-by":"publisher","first-page":"7353","DOI":"10.1016\/S0021-9258(20)89453-8","article-title":"Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces","volume":"266","author":"Naito","year":"1991","journal-title":"J Biol Chem"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/bloodadvances.2019000425","article-title":"Coagulation factor XII contributes to hemostasis when activated by soil in wounds","volume":"4","author":"Juang","year":"2020","journal-title":"Blood Adv"},{"key":"B151","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fmed.2017.00019","article-title":"Factors XI and XII as targets for new anticoagulants","volume":"4","author":"Weitz","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B152","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41569-023-00872-4","article-title":"Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale","volume":"20","author":"Gigante","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1182\/blood-2011-05-355248","article-title":"Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding","volume":"118","author":"Revenko","year":"2011","journal-title":"Blood"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1182\/bloodadvances.2022007586","article-title":"Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation","volume":"7","author":"Tweddell","year":"2023","journal-title":"Blood Adv"},{"key":"B155","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B160","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"B162","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.jaci.2018.06.014","article-title":"Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation","volume":"142","author":"Cao","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/cts.13180","article-title":"A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab","volume":"15","author":"McKenzie","year":"2022","journal-title":"Clin Transl Sci"},{"key":"B165","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet (London, England)"},{"key":"B167","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s11010-021-04315-x","article-title":"Inhibition of NETosis for treatment purposes: friend or foe?","volume":"477","author":"Chamardani","year":"2022","journal-title":"Mol Cell Biochem"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1030991","DOI":"10.3389\/fphar.2022.1030991","article-title":"Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro","volume":"13","author":"Baron","year":"2022","journal-title":"Front Pharmacol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood-2016-11-752840","article-title":"Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis","volume":"130","author":"Machlus","year":"2017","journal-title":"Blood"},{"key":"B170","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-023-37709-0","article-title":"Smart thrombosis inhibitors without bleeding side effects via charge tunable ligand design","volume":"14","author":"La","year":"2023","journal-title":"Nat Commun"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1272971\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T11:26:17Z","timestamp":1698060377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1272971\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":170,"alternative-id":["10.3389\/fcvm.2023.1272971"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1272971","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"article-number":"1272971"}}